Skip to main content
main-content

01.12.2017 | Protocol | Ausgabe 1/2017 Open Access

Systematic Reviews 1/2017

Cancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studies

Zeitschrift:
Systematic Reviews > Ausgabe 1/2017
Autoren:
Ferrán Catalá-López, Brian Hutton, Jane A. Driver, Matthew J. Page, Manuel Ridao, José M. Valderas, Adolfo Alonso-Arroyo, Jaume Forés-Martos, Salvador Martínez, Ricard Gènova-Maleras, Diego Macías-Saint-Gerons, Benedicto Crespo-Facorro, Eduard Vieta, Alfonso Valencia, Rafael Tabarés-Seisdedos
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13643-017-0466-y) contains supplementary material, which is available to authorized users.

Abstract

Background

The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer.

Methods/design

We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer’s disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down’s syndrome, epilepsy, Huntington’s disease, multiple sclerosis, Parkinson’s disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes.

Discussion

Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes.

Systematic review registration

PROSPERO CRD42016052762
Zusatzmaterial
Additional file 1: PRISMA-P Checklist (DOCX 27 kb)
13643_2017_466_MOESM1_ESM.docx
Additional file 2: Key terms for PubMed/MEDLINE search (DOCX 22 kb)
13643_2017_466_MOESM2_ESM.docx
Additional file 3: Definitions of specific cancer-site outcomes (DOCX 26 kb)
13643_2017_466_MOESM3_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Systematic Reviews 1/2017 Zur Ausgabe